Pediatric Praziquantel Consortium
Consortium intensifies its focus on future access
In September the Levo-Praziquantel 150mg Phase 3 trial was initiated in Kenya. With the project moving towards...
From the Program Lead: The Consortium has started the Phase III trial and is preparing for access
The pivotal phase III study with the L-praziquantel pediatric oral dispersible tablets (ODTs) has started, shortly...
A new formulation to fight Schistosomiasis
A pediatric formulation of Praziquantel has been developed for schistosomiasis.
Video credits: The GHIT Fund
Vision
Our vision is to reduce the global disease burden of schistosomiasis by addressing the medical need of infected preschool-age children including infants and toddlers.
Mission
Our mission is to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in preschool-age children.
Development program
Soon after its formation, the consortium established a pediatric drug development program, divided into two major steps: preclinical development, and clinical development.
The pediatric formulation
A new child-appropriate praziquantel formulation is essential for treating children under 6 years of age. The formulation is a small, orally dispersible tablet with an acceptable taste.
